{"id":"W4306926620","doi":"10.1016/j.ygyno.2022.08.021","title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma","year":2022,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; Genentech; National Institutes of Health; PharmaMar; Seagen; NRG Oncology; Ipsen; Clovis Oncology; Gateway Foundation; Eisai; National Comprehensive Cancer Network; Regeneron Pharmaceuticals; Mersana Therapeutics; Shire; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Oncology; Clinical trial; PARP inhibitor; Loss of heterozygosity; Placebo; Randomized controlled trial; Polymerase; Pathology; Gene; Genetics; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001795333,0.0001308731,0.0002898556,0.0003099384,0.0003274154,0.0004758133,0.0001908516,0.0003267767,0.001392036],"category_scores_gemma":[0.0005961361,0.0000842758,0.0003294308,0.0004457275,0.0001736895,0.0002671507,0.0002191989,0.0004342197,0.0002094988],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000265825,"about_ca_system_score_gemma":0.0002584954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007559752,"about_ca_topic_score_gemma":0.001388303,"domain_scores_codex":[0.9998578,0.00001193228,0.00001401239,0.00003216522,0.00002130713,0.00006272124],"domain_scores_gemma":[0.9997484,0.00004814002,0.00006368024,0.00001768235,0.00002517962,0.00009699572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00144161,0.0001413558,0.975349,0.0000157353,0.00007175925,0.003187112,0.00007513817,0.0002584492,0.00368728,0.0001716957,0.0005814625,0.01501943],"study_design_scores_gemma":[0.00006353653,0.0005287279,0.9862379,0.000007819775,0.00008498674,0.00885024,0.0002318564,0.0008237967,0.0005818798,0.0002925452,0.002281367,0.00001524275],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980819,0.0002146311,0.00008574366,0.00007282851,0.00001035205,0.00001123311,0.0002403528,0.000004665696,0.00127823],"genre_scores_gemma":[0.999153,0.00005661776,0.00005810231,0.00005921766,0.00001494817,0.000005617622,0.0004225157,0.000002020025,0.0002278486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001392036,"threshold_uncertainty_score":0.004656851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0388994921237036,"score_gpt":0.3305733788332055,"score_spread":0.291673886709502,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}